New drug trial targets hardening skin in rare autoimmune disease
NCT ID NCT07047690
Summary
This study is testing whether nemolizumab can reduce skin thickening and improve overall health in adults with systemic sclerosis, a rare autoimmune disease that causes skin and organ scarring. About 162 participants will receive either the drug or a placebo for 52 weeks to find the best dose and check safety. The main goal is to see if the treatment can soften hardened skin and potentially slow disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.